CPC A61L 27/3852 (2013.01) [A61L 27/24 (2013.01); A61L 27/3817 (2013.01); A61L 27/3834 (2013.01); A61L 27/3687 (2013.01); A61L 2430/06 (2013.01)] | 21 Claims |
1. An in situ polymerizable collagen-based injectable composition for cartilage defect repair or treatment by injection comprising:
(i) an injectable, in situ polymerizable collagen composition comprising: a neutralized solution comprising acid soluble collagen, EDTA or EGTA and a polyol, wherein the acid soluble collagen in the solution has not undergone fibrillogenesis prior to injection and is selected from one or more of Type I collagen, Type II collagen, and Type III collagen, wherein said acid soluble collagen is in a concentration of 5 to 70 mg/ml; and
(ii) chondrocytes or stem cells comprised in part (i), wherein the in situ polymerizable collagen composition serves as an injectable scaffold supporting cell proliferation; and
(iii) optionally, substance(s) for enhancing cartilage defect repair or treatment and/or for enhancing cell proliferation and function; and/or
(iv) optionally, a slowly resorbable scaffold or micro-carriers,
wherein the in situ polymerizable collagen-based injectable composition with cellular components is in a form that rapidly undergo gelation and polymerization when contacted by physiological fluids and serves as a scaffold supporting cell proliferation.
|